UCSD CIT – Actively Enrolling Trials

SLE

• Anifrolumab (anti-INFr mAb); 2 studies, in renal and non-renal SLE
• NIH sponsored MMF withdrawal study (SLE patients stable on MMF)
• Anti-CD19 mAb in active, non-renal SLE 
• Abatacept in SLE with arthritis
• Baricitnib (jakinib) 2 studies in renal and non-renal SLE 
• RNAase-Fc fusion protein for lupus skin disease

Rheumatoid Arthritis (RA)

•  - 3 studies of a new jakinib (filgotinib), all followed by open label extension
• - MTX-naïve
• - MTX incomplete responder
• - TNFi exposed
• - Rituximab vs rituximab biosimilar; open label treatment available!

• Anti-IL-17A mAb (secukinumab) in PsA (TNFi naïve); open label extension!
• Anti-IL-17A/F mAb (bimekizumab) in AS; TNFi failure allowed; open label extension!

Ankylosing Spondylitis (AS)

• Anti-IL-17A/F mAb (bimekizumab) in AS; TNFi failure allowed; open label extension!